Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

45.39 -0.35 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 845,715
Open 46.54
Bid (Size) 45.25 (3)
Ask (Size) 46.55 (3)
Prev. Close 45.74
Today's Range 45.22 - 46.97
52wk Range 38.94 - 72.00
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors. 
Via Benzinga
Why Editas Medicine Stock Is Soaring Today
Investors are cheering a big analyst upgrade for the gene-editing stock. 
Via The Motley Fool

Performance

YTD
+10.71%
+10.71%
1 Month
-10.15%
-10.15%
3 Month
-19.15%
-19.15%
6 Month
+0.35%
+0.35%
1 Year
-29.62%
-29.62%

More News

Read More
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
Via The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
Via Investor's Business Daily
Exposures Product Safety
2 Bargain Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
Via InvestorPlace
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
Via The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Where Will CRISPR Therapeutics Be in 5 Years?
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
2 Top Trends to Invest $500 In Right Now
Via The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
Via The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
Via The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
3 Top Healthcare Stocks Defying the Bear Market
Via The Motley Fool
Better Bull Market Buy: CRISPR vs. Medtronic Stock
Via The Motley Fool
3 Biotech Blockbusters to Turn $5,000 Into $50,000
Via InvestorPlace
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.